Date: 2012-01-30
Type of information: Grant
Company: Algenics (France)
Investors: OSEO (France)
Amount: undisclosed - This grant is part of a €700 000 phase 1 project.
Funding type: grant
Planned used: This grant will help support the establishment of an alternative and robust technology for manufacturing of monoclonal antibodies. The ongoing program aims at producing a biobetter of an antibody that has been successfully used in the treatment of various cancers. This second generation biotherapeutic will benefit from features of the microalgal cell line PTA to achieve enhanced biological properties while ensuring compliance with upstream & downstream processes suitable for secreted products into chemically-defined culture medium.
Others: Algenics, the biopharmaceutical company offering a microalgae-based solution for the development of recombinant biotherapeutics, has received a grant from OSEO, the French innovation agency, with the support of the European Regional Development Fund.
Therapeutic area: Technology - Services
